A Phase III double-blind, randomized, parallel-group superiority trial to evaluate efficacy and safety of the combined use oforal BI 690517 and empagliflozin compared with placebo andempagliflozin in participants with symptomatic heart failure (HF: NYHAII-IV) and left ventricular ejection fraction (LVEF) ≥40%.
The purpose of this clinical research trial is to look at the effectiveness, safety, and tolerance of combining the investigational trial drug called BI 690517 with empagliflozin (empa) in participants diagnosed with heart failure (HF). Empagliflozin is approved by the FDA for the treatment of heart failure. In this trial, the investigational new treatment option […]
